Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis
1. SCLX's Gloperba® received FDA Orphan Drug designation for pericarditis treatment. 2. Gloperba® is a liquid version of colchicine for treating gout flares. 3. Orphan designation offers exclusivity, enhancing market potential for Gloperba®. 4. SCLX aims to commercialize non-opioid pain management products for various conditions. 5. FDA approval marks a significant milestone for SCLX's product pipeline.